Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Nathaniel J, Myall"'
Autor:
Michael F. Gensheimer, Divya Gupta, Manali I. Patel, Touran Fardeen, Rachel Hildebrand, Winifred Teuteberg, Briththa Seevaratnam, Mary Khay Asuncion, Nina Alves, Brian Rogers, Jennifer Hansen, Jan DeNofrio, Nigam H. Shah, Divya Parikh, Joel Neal, Alice C. Fan, Kaidi Moore, Shann Ruiz, Connie Li, Ali Raza Khaki, Judy Pagtama, Joanne Chien, Tiffany Brown, Alison Holmes Tisch, Millie Das, Sandhya Srinivas, Mohana Roy, Heather Wakelee, Nathaniel J. Myall, Jane Huang, Sumit Shah, Howard Lee, Kavitha Ramchandran
Publikováno v:
JCO Oncology Practice. 19:e176-e184
PURPOSE: Patients with metastatic cancer benefit from advance care planning (ACP) conversations. We aimed to improve ACP using a computer model to select high-risk patients, with shorter predicted survival, for conversations with providers and lay ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afffb13b115ac731997c58aff65b1633
https://doi.org/10.1200/op.22.00128
https://doi.org/10.1200/op.22.00128
Autor:
Xiaodong Gu, Wenxian Wang, Wei Wu, Yiping Zhang, Lan Shao, Mariacarmela Santarpia, Petros Christopoulos, Nathaniel J. Myall, Zhiyong Shi, Guangyuan Lou
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Anaplastic lymphoma kinase (ALK) fusion is an important oncogenic driver in non-small cell lung cancer (NSCLC). Reports on the intergenic region (IGR) as an ALK fusion partner are rare. Here, we report the case of a patient with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::727ce01649f9fc196572a53f616a610d
https://doi.org/10.21037/tlcr-22-288
https://doi.org/10.21037/tlcr-22-288
Autor:
Fangdi Sun, Nathaniel J. Myall, Sumi Sinha, Rao Mushtaq, Steve Braunstein, Heather A. Wakelee, Seema Nagpal, Nicholas J. Thomas, Caroline E. McCoach, Erqi L. Pollom, Tejas Patil, Chad G. Rusthoven, D. Ross Camidge, Chandler Yu
Publikováno v:
Journal of Thoracic Oncology. 17:116-129
Introduction Management of central nervous system (CNS) metastases in patients with driver-mutated NSCLC has traditionally incorporated both tyrosine kinase inhibitors (TKIs) and intracranial radiation. Whether next generation, CNS-penetrant TKIs can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c2ad641e53a7c04fe7ed9812b886050
https://doi.org/10.1016/j.jtho.2021.08.009
https://doi.org/10.1016/j.jtho.2021.08.009
Publikováno v:
NeuroImage: Clinical, Vol 11, Iss C, Pp 555-565 (2016)
Diffusion properties of white matter tracts have been associated with individual differences in reading. Individuals born preterm are at risk of injury to white matter. In this study we compared the associations between diffusion properties of white
Externí odkaz:
https://doaj.org/article/8220365e58324ab1965545aee522e219
Publikováno v:
Neuro-oncology Advances
Brain metastases are a common occurrence in both non-small cell and small cell lung cancer with the potential to affect quality of life and prognosis. Due to concerns about the accessibility of the central nervous system by systemic chemotherapy agen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7734f4190dec75209a8dbd1083b615f6
http://europepmc.org/articles/PMC8633733
http://europepmc.org/articles/PMC8633733
Autor:
Nicholas J. Thomas, Nathaniel J. Myall, Fangdi Sun, Tejas Patil, Rao Mushtaq, Chandler Yu, Sumi Sinha, Erqi L. Pollom, Seema Nagpal, D. Ross Camidge, Chad G. Rusthoven, Steve E. Braunstein, Heather A. Wakelee, Caroline E. McCoach
Publikováno v:
Journal of Thoracic Oncology. 17:e12-e14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6474bc9c99278cc311802b429021651
https://doi.org/10.1016/j.jtho.2021.11.017
https://doi.org/10.1016/j.jtho.2021.11.017
Autor:
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A. Nebhan, Ibiayi Dagogo-Jack, Nathaniel J. Myall, Georg Richtig, Jillian W.P. Bracht, Marco Gerlinger, Eiji Shinozaki, Takayuki Yoshino, Daisuke Kotani, Jason R. Fangusaro, Oliver Gautschi, Julien Mazieres, Jeffrey A. Sosman, Scott Kopetz, Vivek Subbiah, Michael A. Davies, Anna L. Groover, Ryan J. Sullivan, Keith T. Flaherty, Douglas B. Johnson, Andrea Benedetti, David W. Cescon, Anna Spreafico, George Zogopoulos, April A.N. Rose
Publikováno v:
JCO precision oncology. 6
PURPOSE Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to molecular characteristics. Consensus treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efeefaa6a334fb0c9e11eeda57365dcf
https://pubmed.ncbi.nlm.nih.gov/35977349
https://pubmed.ncbi.nlm.nih.gov/35977349
Autor:
Nicholas P, Giustini, Sandip Pravin, Patel, Nathaniel J, Myall, José, Fernando do Prado Moura, Amit, Kulkarni, Richard C, Chao, Heather, Wakelee, Lyudmila, Bazhenova
Publikováno v:
JCO precision oncology. 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::085e88ab69162a10d34fc2c918f7c3fd
https://pubmed.ncbi.nlm.nih.gov/35952324
https://pubmed.ncbi.nlm.nih.gov/35952324
Autor:
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A. Nebhan, Ibiayi Dagogo-Jack, Nathaniel J. Myall, Georg Richtig, Jillian W. P Bracht, Marco Gerlinger, Eiji Shinozaki, Takayuki Yoshino, Daisuke Kotani, Jason R. Fangusaro, Oliver Gautschi, Julien Mazieres, Jeffrey A. Sosman, Scott Kopetz, Vivek Subbiah, Michael A. Davies, Anna Groover, Ryan J. Sullivan, Keith T. Flaherty, Douglas B. Johnson, Andrea Benedetti, David W. Cescon, Anna Spreafico, George Zogopoulos, April A. N. Rose
PurposeNon-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers in a wide array of cancer types and can be classified into three Classes according to molecular ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db9974e1edba3dd315567ab7951bcfce
https://doi.org/10.1101/2022.02.17.22271120
https://doi.org/10.1101/2022.02.17.22271120
Autor:
Joel W. Neal, Nathaniel J. Myall, Sarah Waliany, Thomas T. Chen, Kavitha Ramchandran, Ronald M. Witteles, Millie Das, Han Zhu, Heather A. Wakelee, Sukhmani K. Padda
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(12)
Introduction Targeted therapies have transformed treatment of driver-mutated metastatic NSCLC. We compared cardiovascular adverse events between and within targeted therapy classes. Methods We used WHO pharmacovigilance database VigiBase to compare o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01cfb3b6b595d76f4e2f9622b43a7bbe
https://pubmed.ncbi.nlm.nih.gov/34418561
https://pubmed.ncbi.nlm.nih.gov/34418561